Development of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor ␣ (TNF-␣) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-␣ in a doseand time-dependent manner in human and murine monocyte/ macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca 2ϩ , production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-␣ production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Mol Pharmacol 68:1301-1310, 2005). Overall, these compounds represent novel FPRL1 agonists that induce TNF-␣, a response distinct from those induced by other known FPR and FPRL1 agonists.
natural and synthetic agents with antimicrobial and antitumor properties, such as imidazoquinolines and taxanes, have been shown to induce a broad range of cytokines in cell culture and/or in vivo (Burkhart et al., 1994; Schön and Schön, 2007) . Furthermore, induction of TNF-␣ by imidazoquinolines has been shown to be mediated through agonist activity toward Toll-like receptor (TLR)-7 and TLR-8 (Schön and Schön, 2007) . In contrast, not much is known regarding specific targets of most other reported small molecules that induce phagocyte TNF-␣ production.
The N-formyl peptide receptors (FPR) are a family of G-protein-coupled receptors (GPCR) involved in host defense and sensing cellular dysfunction (for review, see Migeotte et al., 2006) . FPR are highly promiscuous receptors that can be activated by a wide range of structurally unrelated nonpeptide and peptide agonists, including synthetic, host-derived, and pathogen-derived agents (Migeotte et al., 2006) . Three FPR subtypes are present in humans (FPR, FPRL1, FPRL2) ; however, eight FPR-related receptors have been identified in mice (Migeotte et al., 2006) . Activation of FPR induces a variety of responses, which are dependent on the agonist, cell type, receptor subtype, and species involved. For example, N-formyl peptides, which are FPR and FPRL1 agonists, induce human phagocyte inflammatory responses, such as intracellular calcium mobilization, production of cytokines, generation of reactive oxygen species (ROS), and chemotaxis (Migeotte et al., 2006) . In contrast, lipoxin A 4 and related analogs, which are agonists of FPRL1, have been shown to promote resolution of inflammatory processes (Serhan, 2007) . Although several nonpeptide agonists of FPR/FPRL1 have been identified in recent years (Migeotte et al., 2006) , no synthetic agonists of FPR/FPRL1 are known to activate phagocyte TNF-␣ production.
We recently screened a chemolibrary of drug-like molecules for their ability to activate phagocytes and identified several novel small-molecule FPR/FPRL1 agonists (Schepetkin et al., 2007) . In the present studies, analysis of the ability of these compounds to induce phagocyte TNF-␣ production showed that five of these compounds induced modest levels of TNF-␣ by macrophages. Analysis of analogs for these compounds resulted in the identification of four arylcarboxylic acid hydrazides that potently induced TNF-␣ production by murine J774.A1 macrophages. Further investigation of the two most potent compounds showed that these agents induced TNF-␣ production in both human and murine cell lines and primary macrophages. These compounds also induced mobilization of intracellular Ca 2ϩ , activated ROS production by murine macrophages and human neutrophils, and activated chemotaxis of human and murine neutrophils. It is noteworthy that analysis of the cellular target of these compounds showed that they were FPRL1 agonists and that their effect on TNF-␣ production was significantly reduced by treatment with pertussis toxin or the FPR/FPRL1 antagonists N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2) and Trp-Arg-Trp-Trp-Trp-Trp-CONH 2 (WRW4). In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands (Edwards et al., 2005) . Overall, these compounds represent novel FPRL1 agonists that induce TNF-␣, a response distinct from those induced by other known FPR and FPRL1 agonists.
Materials and Methods
Materials. All synthetic small-molecule compounds were obtained from TimTec Inc. (Newark, DE) . 8-Amino-5-chloro-7-phenylpyridol [3,4-d] pyridazine-1,4(2H,3H)-dione (L-012) was obtained from Wako Chemicals (Richmond, VA). Actinomycin D (ActD), cycloheximide (CHX), concanavalin A, dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic acid (EDTA), ionomycin, horseradish peroxidase, N-formyl-Met-Leu-Phe (fMLF), Percoll, HEPES, Histopaque 1077, Histopaque 1119, LPS from Escherichia coli K-235, genistein, and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma Chemical Co. (St. Louis, MO). Interleukin (IL)-8 and keratinocyte-derived chemokine (KC) were obtained from PeproTech Inc. (Rocky Hill, NJ). Pertussis toxin (PTX), WKYMVm, Go6976, U73122, wortmannin, inhibitor B kinase 2 inhibitor VI, and human granulocyte macrophage-colony stimulating factor were purchased from Calbiochem (San Diego, CA). Fura-2 AM was from Invitrogen (Carlsbad, CA). The receptor antagonists N-t-butoxycarbonyl-PheLeu-Phe-Leu-Phe (Boc-2) and WRWWWW (WRW4) were obtained from Phoenix Pharmaceuticals (Belmont, CA). Dulbecco's modified Eagle's medium (DMEM) and Hanks' balanced salt solutions (HBSS, 10ϫ), pH 7.4 [without phenol red; with and without Ca 2ϩ and Mg
2ϩ
(HBSS ϩ and HBSS Ϫ , respectively)], and enzyme-free cell dissociation buffer were from Invitrogen. RPMI 1640 medium was purchased from Mediatech (Herdon, VA). Percoll stock solution was prepared by mixing Percoll with 10ϫ HBSS at a ratio of 9:1.
Cell Culture. Murine macrophage J774.A1 cells were cultured in DMEM supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 10 mM HEPES, 100 g/ml streptomycin, and 100 U/ml penicillin. Cells were grown to confluence in sterile tissue culture flasks and gently detached by scraping. Human monocyte/macrophage MonoMac6 cells (DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS, 10 g/ml bovine insulin, 100 g/ml streptomycin, and 100 U/ml penicillin. Rat basophilic leukemia (RBL-2H3) cells transfected with human FPR (RBL-FPR) or FPRL1 (RBL-FPRL1) were cultured in DMEM supplemented with 20% (v/v) FBS, 10 mM HEPES, 100 g/ml streptomycin, and 100 U/ml penicillin, as described previously (Nanamori et al., 2004) . Human monocytic THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS, 100 g/ml streptomycin, and 100 U/ml penicillin. Human monocytic THP1-Blue cells obtained from InvivoGen (San Diego, CA) were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS, 100 g/ml streptomycin, 100 U/ml penicillin, 100 g/ml Zeocin, and 10 g/ml blasticidin S. These cells are stably transfected with a secreted embryonic alkaline phosphatase gene that is under the control of a promoter inducible by nuclear factor B (NF-B). All cultured cells were grown at 37°C in a humidified atmosphere containing 5% CO 2 . Cell number and viability were assessed microscopically using trypan blue exclusion.
Isolation of Murine Bone Marrow Neutrophils and Peritoneal Macrophages. All animal use was conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee at Montana State University. Bone marrow leukocytes were flushed from tibias and femurs of BALB/c mice with HBSS Ϫ supplemented with 0.1% BSA and 1% glucose and the neutrophils were purified on Percoll density gradients, as described previously (Schepetkin et al., 2007) .
Peritoneal macrophages were isolated from BALB/c mice 4 days after intraperitoneal injection of 1 ml of saline containing 100 g of concanavalin A. Peritoneal exudate cells were suspended in RPMI 1640 medium containing 10% (v/v) FBS with antibiotics (penicillin and streptomycin) and incubated at 37°C in 100-mm tissue culture dishes for 1 h. Adherent peritoneal macrophages were harvested and cultured with the compounds under investigation for 24 h at 37°C and 5% CO 2 .
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at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org Isolation of Human Neutrophils and Monocyte/Macrophages. Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Neutrophils were purified from the blood using dextran sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as described previously (Schepetkin et al., 2007) . Isolated neutrophils were washed twice and resuspended in HBSS Ϫ . Neutrophil preparations were routinely Ͼ95% pure, as determined by light microscopy, and Ͼ98% viable, as determined by trypan blue exclusion.
Monocytes were isolated from blood using dextran sedimentation, Histopaque 1077 gradient separation. Adherent monocytes were cultured for 7 days in RPMI 1640 medium containing 10% FBS and 50 ng/ml granulocyte macrophage-colony stimulating factor to induce macrophage differentiation. was added to the cell suspension (2.25 mM final), and 100 l were aliquotted into the wells of a flat-bottomed black microtiter plate (2 ϫ 10 5 cells/well). The compound source plate contained dilutions of test compounds in HBSS ϩ . Changes in fluorescence were monitored ( ex ϭ 485 nm, em ϭ 525 nm) every 5 s for 240 to 500 s at room temperature after automated addition of compounds to the cells. Maximum change in fluorescence, expressed in arbitrary units over baseline, was used to determine agonist response. Curve fitting and calculation of median effective concentration values (EC 50 ) were performed by nonlinear regression analysis of the dose-response curves generated using Prism 5 (GraphPad Software, Inc., San Diego, CA).
J774A.1 macrophages suspended in HBSS Ϫ containing 10 mM HEPES were loaded with Fura-2AM dye (2 g/ml final concentration) and incubated for 30 min in the dark at 37°C. After dye loading, the cells were washed with HBSS Ϫ containing 10 mM HEPES, resuspended in 1.5 ml of HBSS ϩ containing 10 mM HEPES, and aliquotted into the wells of a flat clear-bottomed, half-area-well black microtiter plate (6 ϫ 10 5 cells/well). The compound source plate contained dilutions of test compounds in HBSS ϩ . Changes in fluorescence were monitored ( ex ϭ 340 and 380 nm, em ϭ 510 nm) every 5 s for 240 to 500 s at 37°C after automated addition of compounds to the wells. Maximum change in ratio of fluorescence values at excitation wavelengths of 340 and 380 nm was used to determine agonist response. Curve fitting and calculations were performed as above.
Chemotaxis Assay. Neutrophils were suspended in HBSS ϩ containing 2% (v/v) FBS (2 ϫ 10 6 cells/ml), and chemotaxis was analyzed in 96-well ChemoTx chemotaxis chambers (Neuroprobe, Gaithersburg, MD), as described previously (Schepetkin et al., 2007) . In brief, lower wells were loaded with 30 l of HBSS ϩ containing 2% (v/v) FBS and the indicated concentrations of test compound, DMSO (negative control), and 50 nM IL-8 as a positive control for human neutrophils or 50 nM KC as a positive control for murine neutrophils. The number of migrated cells was determined by measuring ATP in lysates of transmigrated cells using a luminescence-based assay (CellTiter-Glo; Promega, Madison, WI), and luminescence measurements were converted to absolute cell numbers by comparison of the values with standard curves obtained with known numbers of neutrophils. The results are expressed as percentage of negative control and were calculated as follows: (number of cells migrating in response to test compounds/spontaneous cell migration in response to control medium) ϫ 100. EC 50 values were determined by nonlinear regression analysis of the dose-response curves generated using Prism 5 software.
Analysis of ROS Production. J774.A1 macrophages were plated at density of 1.5 ϫ 10 5 cells/well in wells of 96-well flatbottomed white microtiter plates (Costar; Corning Life Sciences, Acton, MA). After 16 h (5% CO 2 , 37°C), the medium was aspirated, and test compounds or vehicle (final DMSO concentration of 1%) were added in fresh medium [DMEM without phenol red, supplemented with 3% (v/v) FBS]. After 5 min, the media was replaced with HBSS ϩ containing 40 M L-012 and 8 g/ml horseradish peroxidase, and luminescence was monitored for 120 min (2-min intervals) at 37°C using a Fluoroscan Ascent FL microtiter plate reader (Thermo Fisher Scientific, Waltham, MA). The curve of light intensity (in relative luminescence units) was plotted against time, and the area under the curve was calculated as total luminescence. The percentage activation of ROS was calculated as follows: percentage activation ϭ (sample-DMSO control)/DMSO control ϫ 100. The minimal compound concentration that enhanced ROS production by 50% above background control cells (AC 50 ) was determined by graphing the percentage activation of ROS versus log [test compound]. Each curve was determined using five to seven compound concentrations.
Human neutrophils were plated at density of 5 ϫ 10 5 cells/well in wells of 96-well flat-bottomed white microtiter plates, and compounds under investigation or vehicle (final DMSO concentration of 1%) were added. After 5 min, the media was replaced by HBSS ϩ containing 40 M L-012, and luminescence was monitored for 120 min (2-min intervals) at 37°C using a Fluoroscan Ascent FL microtiter plate reader. The results were analyzed as described above to determine percentage activation and AC 50 values.
Determination of TNF-␣ and IL-6. Cells were treated for 24 h with DMSO control, test compound, or LPS and mouse TNF-␣ or IL-6 and human TNF-␣ enzyme-linked immunosorbent assay (ELISA) kits (BD Biosciences Pharmingen, San Diego, CA) were used to detect these cytokines in the cell supernatants. Cytokine concentrations were determined by extrapolation from TNF-␣/IL-6 standard curves, according to the manufacturer's protocol.
For treatments, cells were plated in 96-well microtiter plates at 2 ϫ 10 5 cells/well (J774.A1, MonoMac6) or 6 ϫ 10 4 cells/well (human monocyte-derived macrophages) using their respective culture media, except FBS was reduced to 3% (v/v). After incubation overnight (5% CO 2 , 37°C), the media were removed and replaced with fresh media containing test compounds.
Analysis of NF-B Activation. Activation of NF-B was measured using an alkaline phosphatase reporter gene assay in THP1-Blue cells. One week before an experiment, the cells were preactivated overnight with PMA (50 ng/ml) to induce differentiation and plated in 96-well plates at a cell density of 2 ϫ 10 5 cells/well. The cells were then incubated for 5 days with daily media changes. On day 7, compounds under investigation were added, the cells were incubated for 24 h, and alkaline phosphatase activity was measured in cell supernatants using QUANTI-Blue mix (InvivoGen, San Diego, CA) and monitoring absorbance at 655 nm in a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA).
Cytotoxicity Assay. Cytotoxicity was analyzed with a CellTiterGlo Luminescent Cell Viability Assay Kit (Promega, Inc., Madison, WI), according to the manufacturer's protocol. In brief, J774.A1 cells were cultured at a density of 3 ϫ 10 4 cells/well with the test compounds for 24 h at 37°C and 5% CO 2 , substrate was added, and luminescence signal in the samples was analyzed with a Fluoroscan Ascent FL.
Endotoxin Assay. Endotoxin was measured using Limulus Amebocyte Lysate Pyrogent Plus (Lonza Walkersville, Walkersville, MD). In brief, the limulus amebocyte lysate was reconstituted in 250 l of test compound solution (50 M in endotoxin-free water/1% DMSO), and each vial was incubated at 37°C for 1 h. At the end of the incubation period, each vial was inverted 180°to estimate gel formation compared with control (endotoxin-free water).
Conformational Analysis. For the selected compounds, sets of conformations were generated using the Conformational Search Module, as implemented in HyperChem Version 7.0 (Hypercube, Inc., Waterloo, ON, Canada). The systematic search of conformations for each compound was performed by energy minimization, starting with 2000 initial geometries at random values of torsion angles about exocyclic single bonds and considering that hydrazide CϭN fragment can adopt syn-or anti-orientation of substituents. Energy was minimized by the Polak-Ribiere conjugate gradient method with MMϩ force field (HyperChem; HyperCube, Gainesville, FL). Attainment of a root-mean-square (RMS) gradient Ͻ0.02 kcal/mol/Å was used as the termination condition for minimization. Conformations were considered equivalent if all the corresponding torsion angles differed by less than 20°among conformations. Results of the conformational search were saved as text files in HCS format adopted in HyperChem. These files were used as input for a computer program that analyzed each conformation and calculated distances between atoms specified by user as potential acceptors of H-bonds or hydrophobic points. We placed the hydrophobic centers in the middle of the benzene rings in compound 2 and in the geometric gravity center of the bromophenyl group in compound 1, whereas the acceptors were positioned at fluorine atoms, pyridine and double-bonded hydrazide nitrogens, and carbonyl and furan oxygen atoms, which are known as H-bond acceptors. The distances calculated for all possible triads of the two H-bond acceptors and single hydrophobic center among all the conformations found were compared with those in the pharmacophore model published previously by Edwards et al. (2005) . The value of was calculated as RMS relative deviation of the distances obtained from the center of corresponding tolerance intervals [A 1 -A 2 (3-6 Å), A 1 -H (5-7 Å), and A 2 -H (4-7 Å)], as determined by Edwards et al. (2005) .
Statistical Analysis. One way analysis of variance was performed on the indicated sets of data, followed by Tukey's pair-wise comparisons (Prism Software). Pair-wise comparisons with differences at P Ͻ 0.05 were considered to be statistically significant.
Results
Identification of TNF-␣ Inducers. We screened previously a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production by phagocytes and identified 26 such agonists [designated here as agonists (AG) 1-26] (Schepetkin et al., 2007) . In the present studies, we evaluated whether these compounds also induced phagocyte TNF-␣ production and found that five compounds induced modest levels of TNF-␣ production by murine J774.A1 macrophages (compounds AG-1, -3, -8, -14, and -15). Because the two most potent compounds (AG-3 and AG-14) are both arylcarboxylic acid hydrazides (Supplemental Table S1 ), we focused on this scaffold and selected analogs for each of these two agonists for further screening. Forty-one analogs of AG-3 and 28 derivatives of AG-14 were selected to obtain a pool of 71 compounds for secondary screening (Supplemental Table S1 ). Analysis of these analogs for their ability to stimulate TNF-␣ production identified 22 additional compounds with various levels of activity (Table 1 and Supplemental Table S1 ). Determination of dose-response relationships for all 24 selected compounds showed that six compounds were quite active and induced TNF-␣ production by J774.A1 macrophages in a concentration-dependent manner (Table 1 and Fig. 1A ). Compounds 1 and 2 were the most active, inducing ϳ50% of the TNF-␣ levels that were induced by the EC 50 concentration of LPS (2 ng/ml). Activation was not due to LPS contamination; however, because analysis of compounds 1 and 2 for LPS using a limulus amebocyte lysate assay showed that these compounds contained no endotoxin (below detection limit; data not shown). TNF-␣ production was induced in a time-dependent manner by compounds 1 and 2 (Fig. 1B) , whereas treatment with these compounds had no effect on cell viability, indicating lack of cytotoxicity (Supplemental Figure S1) . Thus, further studies focused primarily on compounds 1 and 2.
To determine whether the up-regulation of TNF-␣ production represented new protein synthesis, J774.A1 macrophages were treated with ActD to inhibit transcription or CHX to inhibit protein synthesis before treatment with active compounds. As shown in Fig. 2 , treatment with either ActD or CHX completely inhibited TNF-␣ production induced by compounds 1 and 2. These results indicate that transcription and de novo protein synthesis are required for the TNF-␣ secretion induced by these arylcarboxylic acid hydrazides.
To investigate the effect of compounds 1 and 2 on TNF-␣ production in macrophages of different lines and species, murine peritoneal macrophages, human monocyte/macrophage cells (THP-1 and MonoMac6), and human monocytederived macrophages were stimulated with various concentrations of these compounds. Both compounds induced TNF-␣ production in a concentration-dependent manner in murine and human cells (Fig. 3) . Note, however, that there was a wide range in the level of TNF-␣ produced by the various cell lines. Furthermore, compound 2 generally had much higher activity in human cells, whereas compound 1 was more potent in activating murine cells. To determine whether the most potent TNF-␣ inducers could also induce IL-6 production, we evaluated levels of IL-6 produced by J774.A1 cells treated with compounds 1 and 2. As shown in Fig. 4 , both compounds induced secretion of IL-6, compound 1 being the more potent of the two. In comparison, com- pounds 3 to 5 and AG-14 all failed to induce macrophage IL-6 production (data not shown). Effect of TNF-␣ Inducers on Phagocyte Chemotaxis and ROS Production. We found previously that treatment of phagocytes with two arylcarboxylic acid hydrazides (AG-14 and AG-104) stimulated phagocyte chemotaxis (Schepetkin et al., 2007) . Thus, we evaluated the effects of compounds 1 and 2 on this response in murine and human phagocytes. Both of these compounds were found to be neutrophil chemoattractants and dose dependently induced human as well as murine neutrophil migration (Supplemental Figure S2) , although the magnitude of these responses was generally lower than that induced by IL-8 or KC for human and murine neutrophils, respectively (Table 2 ). In comparison, maximal chemotaxis toward compound AG-14 was equal to or much higher than the response induced by 50 nM IL-8 or KC, respectively. Note that the dose-response curves for murine neutrophil chemotaxis were bell-shaped, whereas the chemotactic responses of human neutrophils increased with increasing dose of compounds up to the maximal dose tested (Supplemental Figure S2) .
Analysis of the ability of compounds 1 and 2 to activate ROS production in human neutrophils and murine J774.A1 macrophages showed that these compounds dose dependently stimulated ROS generation in both types of cells, with AC 50 values in the high nanomolar to low micromolar range (Fig. 5 and Table 2 ). Likewise, compound AG-14 activated phagocyte ROS production, which was consistent with our previous analysis of this compound (Schepetkin et al., 2007) .
Effect of TNF-␣ Inducers on Ca 2؉ Mobilization in Neutrophils and Macrophages. All 71 selected arylcarboxylic acid hydrazides were evaluated for their ability to induce Ca 2ϩ mobilization in human neutrophils. From this screening, we found that 30 of the 71 compounds induced Ca 2ϩ mobilization in neutrophils with EC 50 values Յ32 M (Supplemental Table S1 ), although there was not a consistent correlation between the ability to induce TNF-␣ production and stimulate Ca 2ϩ flux. Nevertheless, the most potent TNF-␣ inducers (Table 1 and Supplemental Table S1 ) also activated Ca 2ϩ mobilization in human neutrophils. As shown in Fig. 6A , compounds 1 and 2 induced transient increases in [Ca 2ϩ ] i that were similar to those induced by fMLF. Previous reports indicated that Ca 2ϩ mobilization is required for TNF-␣ production in macrophages stimulated by various agents (e.g., Watanabe et al., 1996) . Thus, we examined the effect of compounds 1 and 2 on Ca 2ϩ mobilization in J774.A1 macrophages. As shown in Fig. 6B , treatment of J774.A1 macrophages with compounds 1 and 2 dose dependently increased [Ca 2ϩ ] i , and calculated EC 50 values for these compounds, as well as compound AG-14, are shown in Table 2 . By comparison, fMLF was much less potent (EC 50 Ͼ 30 M). As a positive control, the Ca 2ϩ ionophore ionomycin increased [Ca 2ϩ ] i within these cells (EC 50 ϭ 0.58 Ϯ 0.3 M). A substantial Ca 2ϩ response to fMLF could not be obtained because of the limited solubility of fMLF; however, this result (0) or the indicated concentrations of compounds 1 (F), 2 (E), 3 (f), 4 (Ⅺ), 5 (᭜), AG-14 (‚), or LPS (2 ng/ml) (छ) for 24 h, and TNF-␣ was measured in the cell supernatants by ELISA. B, macrophages (2 ϫ 10 5 cell/well) were cultured in the presence of the 12.5 M compound 1 (F), compound 2 (E), or DMSO (f) for the indicated times, and TNF-␣ was measured in the cell supernatants by ELISA. The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment that is representative of three independent experiments. Fig. 2 . Effect of actinomycin D and cycloheximide on compound-induced TNF-␣ production by J774.A1 macrophages. J774.A1 macrophages were pretreated with ActD (1 g/ml), CHX (5 g/ml), or control DMSO for 30 min, followed by addition of 50 M compound 1 (open bars) or compound 2 (solid bars) for 12 h. TNF-␣ was measured in the cell supernatants by ELISA. The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment, which is representative of three independent experiments. is consistent with previous studies showing that mouse cells express only low-affinity receptors for fMLF (Gao et al., 1998) .
TNF-␣ Inducers Activate Ca 2؉ Mobilization through FPR or FPRL1. We demonstrated perviously that compound AG-14 activated neutrophils through stimulation of FPR/FPRL1, although the receptor subtype specificity was not evaluated (Schepetkin et al., 2007) . Thus, we analyzed whether compounds 1 and 2 were also FPR/FPRL1 agonists. In addition, we evaluated receptor subtype specificity for these two compounds, as well as for compound AG-14, using RBL-2H3 cells transfected with human FPR (RBL-FPR cells) or FPRL1 (RBL-FPRL1 cells) (Nanamori et al., 2004) . Compounds 1 and 2 both induced a dose-dependent increase of [Ca 2ϩ ] i in RBL-FPRL1 cells, whereas no response was observed in wild-type or RBL-FPR cells treated with either of these compounds (Fig. 7 and Table 3 ). In comparison, compound AG-14 induced a dose-dependent increase of [Ca 2ϩ ] i in RBL-FPR cells but had no effect on wild-type or RBL-FPRL1 cells ( Fig. 7C and Table 3 ). Thus, these data indicate that compounds 1 and 2 are novel FPRL1-specific agonists, whereas compound AG-14 is specific for FPR.
FPRL1 is a GPCR and signals through PTX-sensitive heterotrimeric G-proteins (G i /G o ) (for review, see Migeotte et al., 2006) . Thus, we evaluated the effects of PTX on TNF-␣ production induced by compounds 1 and 2. As shown in Fig. 8A , PTX significantly inhibited the production of TNF-␣ induced by compounds 1 and 2. In comparison, PTX had little or no effect on the LPS-induced TNF-␣ response. This observation is consistent with previous studies showing that PTX failed to block LPS-induced production of TNF-␣ or other cytokines by macrophages (e.g., Zhang and Morrison, 1993) . As a control to verify the effectiveness of PTX, we evaluated the effect of PTX on [Ca 2ϩ ] i mobilization in human neutrophils treated with fMLF and our compounds. Consistent with previous reports (Kelher et al., 2003) , PTX inhibited the Ca 2ϩ flux induced by fMLF (Supplemental Figure S3) . Likewise, PTX significantly inhibited [Ca 2ϩ ] i mobilization induced by compounds 1 and 2 (Supplemental Figure S3) . In addition, cell viability was not significantly affected in cells treated with PTX (data not shown). Thus, these results provide further evidence that compounds 1 and 2 are indeed FPRL1 agonists.
The ability to induce TNF-␣ production via the FPR or FPRL1 pathways was quite specific to the compounds we identified here, because both of the peptide agonists, fMLF and WKYMVm, failed to induce macrophage TNF-␣ production (Fig. 8B) . However, these results did not rule out the possibility that compounds 1 and 2 could be activating TNF-␣ production through a different pathway in these cells. To address this issue, we evaluated the effects of Boc-2, an antagonist of FPR/FPRL1 (Gavins et al., 2003) , and WRW4, an antagonist of FPRL1 (Bae et al., 2004) . As shown in Fig.  8C , both antagonists inhibited TNF-␣ production induced by compounds 1 and 2 in J774.A1 macrophages, directly demonstrating that both compounds were inducing TNF-␣ production through FPRL1. Fig. 3 . Analysis of TNF-␣ production induced by compounds 1 and 2 in murine peritoneal macrophages, human monocytic cells THP-1, human MonoMac6 macrophages, and human monocyte-derived macrophages. The indicated cells were incubated with buffer (0) or the indicated concentrations of compound 1 (E), compound 2 (F), or LPS (50 ng/ml) (ࡗ) for 24 h, and TNF-␣ was measured in the cell supernatants by ELISA. The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment that is representative of three independent experiments.
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Because TNF-␣ production can be activated via the NF-B pathway, we considered whether the ability of these agonists to stimulate TNF-␣ production might be related to the amplitude of NF-B induction. Using a transcription factor-based bioassay for NF-B activation in human THP-1 monocytes, we found that compounds 1, 2, and AG-14, as well as fMLF and WKYMVm, all stimulated NF-B activity at comparable levels (Supplemental Figure S4) . Note, however, that NF-B activation by these agonists was still much lower than that induced by LPS (Supplemental Figure S4) . Thus, the ability of a given FPR/FPRL1 agonist to induce TNF-␣ production does not seem to be due to differential induction of NF-B.
Phagocyte stimulation by FPRL1 agonists activates a number of intracellular signaling pathways in addition to the NF-B pathway, including those involving phospholipase C, phosphatidylinositol 3-kinase, protein kinase C, and tyrosine kinases (for review, see Migeotte et al., 2006) . Thus, we evaluated the role of these pathways in TNF-␣ production induced by compounds 1 and 2 specific pathway inhibitors. It is noteworthy that pretreatment of J774.A1 macrophages with a phospholipase C inhibitor (U73122), a phosphoinositide 3-kinase inhibitor (wortmannin), a tyrosine kinase inhibitor (genistein), a protein kinase C ␣/␤ inhibitor (Go6976), or an inhibitor B kinase 2 inhibitor (inhibitor B kinase 2 inhibitor VI) significantly inhibited TNF-␣ production induced by compounds 1 and 2 as well as by LPS (Supplemental Figure S5 ). In contrast, the LPS response was not affected by PTX pretreatment (Fig. 8 and Supplemental Figure S5 ). Note that cell viability was not significantly altered in cells treated with these concentrations of inhibitors, and the inhibitors alone induced no TNF-␣ secretion (data not shown).
Molecular Modeling. Edwards et al. (2005) developed a pharmacophore model for FPR ligands that was based on docking of known receptor agonists and antagonists onto a homology model of the receptor. This model, which contains two acceptors for H-bonding and one hydrophobic point, was used previously to demonstrate how the low-energy conformations of six small-molecule neutrophil agonists, including AG-14, fit structural requirements for ligand bioactivity (Schepetkin et al., 2007) . Visual inspection of structures of compounds 1 and 2 showed that each of these compounds contained several potential acceptors for H-bonding and at least one hydrophobic center. Thus, we evaluated whether compounds 1 and 2 also fit with this pharmacophore model.
Considering that these compounds are flexible molecules, we explored their potential energy surfaces using a conformational search with an MMϩ force field, and the conformations within an energy gap of 6 kcal/mol over the global minimum (Nicklaus et al., 1995) were stored. The numbers of nonequivalent conformations within 6 kcal/mol of the global minimum found for compounds 1 and 2 were 90 and 120, respectively. Best-fit conformations for these compounds, together with calculated distances, best RMS fit (), and conformational energy are shown in Fig. 9 . The most active compound (compound 1) had two conformations that fit quite well into the pharmacophore model. Distances A 1 -H and A 2 -H in the conformation with the lowest RMS fit were essentially equivalent (Fig. 9) , hence an additional good fit ( ϭ 4.3%) is possible for this same conformation by switching the two H-bond acceptors such that A 1 is now the pyridine nitrogen and A 2 is the carbonyl oxygen. The next fit of lower quality ( ϭ 9.1%) corresponded to a conformation with the same location of A 2 and H as shown in Fig. 9 , but with A 1 located on the double-bonded hydrazide nitrogen. The best fit for compound 2 ( ϭ 4.5%) was also well within the tolerance range reported for the ligand pharmacophore (Edwards et al., 2005) .
Discussion
Phagocytic cells play a key role in innate immunity because of their ability to recognize, ingest, and destroy pathogens by oxidative and nonoxidative mechanisms (Tosi, 2005) . These responses are modulated by a variety of extrinsic factors, including bacterial products, lipids, cytokines, and che- Fig. 4 . Effect of compounds 1 and 2 on IL-6 production in murine J774.A1 macrophages. Macrophages (2 ϫ 10 5 cells/well) were cultured in the presence of compound 1 (E), compound 2 (F), or LPS (50 ng/ml) (ࡗ) for 24 h, and TNF-␣ was measured in the cell supernatants by ELISA. Background IL-6 production induced by control DMSO was negligible (not shown). The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment, which is representative of three independent experiments. mokines, and it is now apparent that the nature of a given inflammatory response represents interplay between proand anti-inflammatory immune modulators (Gordon, 2007) . Because one of the key factors regulating phagocyte inflammatory responses is TNF-␣, we screened a library of chemically related compounds to identify unique small-molecule activators of phagocyte TNF-␣ production.
In primary screening, we identified two lead compounds with modest activity. Because these compounds were both arylcarboxylic acid hydrazides, we used this chemical scaffold to select additional analogs for secondary screening, and the two most potent arylcarboxylic acid hydrazides were selected for further characterization. The array of neutrophil responses induced by these compounds suggested that they were possibly GPCR agonists. Indeed, our previous study showed that a related compound (AG-14) was an FPR/FPRL1 agonist (Schepetkin et al., 2007) . Thus, we considered whether compounds 1 and 2 might also be FPR/FPRL1 agonists, albeit unique because none of the known FPR/FPRL1 agonists have been reported to induce TNF-␣ production, and neither fMLF nor WKYMVm was able to induce macrophage TNF-␣ production. In fact, it has been reported that fMLF can actually inhibit TNF-␣ production by LPS-stimulated neutrophils (Vulcano et al., 1998) .
To directly evaluate whether compounds 1 and 2 were FPR/ FPRL1 agonists, we studied their ability to induce [Ca 2ϩ ] i mobilization in cells expressing either FPR or FPRL1. Compounds 1 and 2 dose dependently activated [Ca 2ϩ ] i mobilization only in cells expressing FPRL1, not in wild-type cells or cells expressing FPR. In contrast, compound AG-14 activated [Ca 2ϩ ] i mobilization only in cells expressing FPR, which may help to explain the differences in responses induced by this compound versus compounds 1 and 2. Thus, although these three compounds are all arylcarboxylic acid hydrazides, their receptor subtype specificity is clearly distinct. Furthermore, a general FPR/FPRL1 antagonist and a specific FPRL1 antagonist were both found to block TNF-␣ induction by compounds 1 and 2, providing direct evidence that this response was mediated through FPRL1. Note, however, that we have not performed an analysis of all possible GPCRs and cannot rule out the possibility that additional GPCRs might also be involved. Because neither of the three compounds induced [Ca 2ϩ ] i mobilization in wild-type RBL cells, our results do indicate that these agonists do not activate other endogenous GPCRs in RBL cells.
Pharmacophore modeling is based on the premise that all ligands of a given target bind in a conformation that presents similar steric and electrostatic features to the target receptor, and these features are recognized by the receptor and are responsible for biological activity (Guner et al., 2004 ). The pharmacophore model used here was developed based on the bovine rhodopsin crystal structure and known FPR ligands (Edwards et al., 2005) . Our molecular modeling showed a high degree of similarity to this previously published pharmacophore model for low-energy conformations of compounds 1 and 2, demonstrating a good agreement between biological activity and the presence of low-energy, best-fit conformations of the compounds with the model. Although our previous conformational analysis showed that one FPRL1 agonist, Quin-C1, did not fit well into the pharmacophore model (Schepetkin et al., 2007) , the present results indicate that the model is not specific only for FPR ligands and that some Fig. 5 . Effect of compounds 1 and 2 on ROS production by human neutrophils. Human neutrophils were treated with the indicated concentrations of compound 1 (E), compound 2 (F), or PMA (50 nM) for 5 min, and luminescence was monitored for 120 min at 37°C, as described. The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment that is representative of three independent experiments. FPRL1 agonists also fit into the model. Overall, pharmacophore modeling provided further support that these compounds do indeed fit the molecular features required for FPR/FPRL1 agonists. There is very little current information on the structure of FPRL1. Thus, we suggest that the arylcarboxylic acid hydrazides reported here and additional analogs may be exploited in the future to probe the requirements for ligand interaction and receptor activation.
Taken together, our data support the conclusion that compounds 1 and 2 activate FPRL1 to induce intracellular signaling events, leading to a number of host defense/inflammatory responses, including the stimulation of TNF-␣ production in macrophages. Note, however, that these compounds must activate distinct arrays of signaling pathways, because the standard peptide agonists of FPR/FPRL1 failed to induce TNF-␣ production. The ability of FPR/FPRL1 agonists to induce TNF-␣ production requires NF-B but does not seem to be related to the relative level of NF-B activation. Thus, activation of phagocyte TNF-␣ production by compounds 1 and 2 is likely to include additional transcriptional regulatory pathways independent of NF-B. Analysis of additional signal transduction pathways involved in phagocyte activation by compounds 1 and 2 implicated a number of pathways known to be involved in FPR/FPRL1 stimulation, including pathways involving phospholipase C␤, phosphatidylinositol 3-kinase ␥, protein kinase C, and protein tyrosine kinase (for review, see Migeotte et al., 2006) . Inhibition of all four of these pathways blocked TNF-␣ production induced by both our compounds as well as by LPS. Thus, similar intercellular signaling components seem to be involved in responses induced by these agonists, although they activate the cell through quite different receptor systems (i.e., FPR/ FPRL1 versus TLR4). Further studies are clearly required to define the nature of the signaling pathways involved in activation of TNF-␣ production by the arylcarboxylic acid hydrazide derivatives described here, and these studies are in progress.
Various natural and synthetic small-molecules have been shown to induce macrophage TNF-␣ production (e.g., Burkhart et al., 1994; Schön and Schön, 2007) . However, the nonpeptide synthetic substances currently known to activate macrophage TNF-␣ production have been shown to be TLR agonists (Byrd-Leifer et al., 2001; Schön and Schön, 2007) . Thus, the compounds described here are unique in their ability to activate this response via a GPCR. On the other hand, compounds with this scaffold have been reported among agents with antitumor (Boykin and Varma, 1970) , proapoptotic (Zhang et al., 2004) , antiprion (Bertsch et al., 2005) , analgesic (Almasirad et al., 2006) , and antioxidant (Simunek et al., 2005) properties. Hence, our findings suggest the possibility that the antitumor and proapoptotic effects reported for arylcarboxylic acid hydrazides could be due, in part, to activation of TNF-␣ production. Indeed, FPR/FPRL1 has been reported to be expressed on human tumor cells, including malignant human glioma cell lines, primary glioblastomas and anaplastic astrocytomas, and epithelial cancer cells, and it has been suggested that this receptor contributes to motility, growth, and angiogenesis (Le et al., 2000; Rescher et al., 2002; Zhou et al., 2005; Huang et al., 2007) . In
Compound 1
E=4.14 kcal/mol, ε=4.2%
Compound 2
E=5.64 kcal/mol, ε=4.5% Fig. 9 . Comparison of best-fit conformations of compounds 1 and 2 with the published three-point pharmacophore model of FPR ligands. The conformations shown represent the best RMS fit () among all energy minima 6 kcal/mol above the global minimum. A 1 , A 2 , and H are the pharmacophore centers corresponding to the H-bond acceptors (A 1 and A 2 ) and hydrophobic center (pseudoatom H, green sphere), with permitted distances (Å) between points as follows: A 1 -A 2 (3-6 Å), A 1 -H (5-7 Å), and A 2 -H (4 -7 Å) (Edwards et al., 2005) . For all structures, carbon atoms are sky blue, nitrogen atoms are blue, oxygen atoms are red, hydrogen atoms are white, fluorine atoms are small yellow spheres, and bromine are large yellow spheres. LPS (50 ng/ml) for 24 h, and TNF-␣ was measured in the cell supernatants by ELISA. Statistically significant differences ‫,ء(‬ P Ͻ 0.001) between responses induced by LPS or compounds 1 and 2 in Boc-2-or WRW4-pretreated versus vehicle-pretreated controls are indicated. The data are presented as the mean Ϯ S.D. of triplicate samples from one experiment that is representative of three independent experiments. Fig. 8 . Characterization of TNF-␣ production induced by compounds 1 and 2 in murine macrophages. A, J774.A1 macrophages (2 ϫ 10 5 cells/ well) were pretreated for 30 min with control buffer (0) or PTX (0.4 and 1 g/ml), followed by the addition of compound 1 (50 M), compound 2 (50 M), or LPS (50 ng/ml) for 12 h, and TNF-␣ was measured in the cell supernatants by ELISA. Statistically significant differences ‫,ء(‬ P Ͻ 0.001) between responses induced in PTX-pretreated versus DMSO-pretreated controls are indicated. B, macrophages (2 ϫ 10 5 cells/well) were cultured in the presence of control DMSO, fMLF (50 M), WKYMVm (50 M), or compound 1 (25 M) for 24 h, and TNF-␣ was measured in the cell supernatants by ELISA. C, macrophages (2 ϫ 10 5 cells/well) were pretreated for 5 min with control DMSO, Boc-2 (40 M), or WRW4 (10 M), followed by the addition of compound 1 (50 M), compound 2 (50 M), or addition, transduction of human FPRL1 into murine tumor cells has been reported to increase host anti-tumor immunity, although this was not due to an antibody response to the foreign antigen, and anti-FPRL1 antibodies were not found . One possibility suggested by the present studies is that expression of FPRL1 in these tumor cells could result in responsiveness to endogenous agonists that induce TNF-␣ production, which would lead to tumor cell apoptosis and destruction (Lejeune et al., 2006; Reed, 2006) . The compounds described here induce much lower levels of TNF-␣ than LPS, and TNF-␣ production occurs gradually over an extended period of time, rather than the rapid and maximal response induced by LPS. Thus, the moderate responses induced by these compounds may alleviate the inflammatory toxicity associated with very strong agonists, such as LPS, and in vivo testing is currently in progress to address this issue.
FPRL1 is a highly promiscuous receptor and responds to a wide array of exogenous and endogenous ligands (for review, see Migeotte et al., 2006) . Likewise, the array of responses induced by these ligands is varied, and the intracellular signals that are activated depend on the ligand, ligand concentration, and cellular features. For example, stimulation of FPRL1 with lipoxin A 4 and/or annexin 1/annexin 1-derived peptides leads to anti-inflammatory responses (Perretti et al., 2002; Serhan, 2007) . On the other hand, inflammatory responses are induced by a number of the other FPRL1 agonists, including N-formyl peptides, cathelicidin antibacterial peptide LL37, the truncated chemokine sCK␤8 -1, and pituitary adenylate cyclase-activating polypeptide 27 (for review, see Migeotte et al., 2006) . Here, we describe an additional class of FPRL1 agonists that induces a unique response. However, given the wide range of responses induced by FPRL1 agonists so far, it is not surprising that additional responses, such as the induction of TNF-␣ production shown here, will eventually be identified as novel ligands for this receptor are found in future screening of compound analogs.
The wide range of agonists and responses of FPRL1 suggests that this receptor may represent a unique target for therapeutic drug design. Here, we identified and characterized specific FPR/FPRL1 agonists that not only have a novel structure but also induce a novel response not seen before with any of the known FPR/FPRL1 agonists. Thus, further development of this class of agonists and analysis of additional derivatives may provide important clues to understanding FPR and FPRL1 structure and function. In addition, FPR/FPRL1 agonists have potential value as immune modulators to enhance phagocyte host defense against pathogens and as possible vaccine adjuvants.
